VI
ESPR

Vestcor Inc’s Esperion Therapeutics ESPR Stock Holding History

Vestcor Inc’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.53M Buy
+800,000
New +$2.24M 0.06% 295

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TH
Transmarket Holdings Chicago, Illinois $136M AUM
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
CIEC
Crédit Industriel et Commercial Paris France, France $1.55B AUM 42.08% 1-Year Est. Return
CCM
Chicago Capital Management Chicago, Illinois $112M AUM 76.54% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Vestcor Inc's ESPR Position: Q2 2026 in Review

Vestcor Inc opened a new position in Esperion Therapeutics (ESPR) in Q2 2026: 800,000 shares worth $2.53M. The stake represents 0.06% of the portfolio and ranks #295 among its holdings.

89 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Vestcor Inc held 800,000 shares of Esperion Therapeutics worth $2.53M as of Q2 2026.
  • Esperion Therapeutics was a new Vestcor Inc position in Q2 2026.
  • Esperion Therapeutics made up 0.06% of Vestcor Inc's portfolio in Q2 2026, its #295 holding.
  • 89 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Vestcor Inc's 13F filing for Q2 2026, filed 11 Aug 2026.